Assessing risk: does this patient have prostate cancer?
作者信息
Carter H Ballentine
出版信息
J Natl Cancer Inst. 2006 Apr 19;98(8):506-7. doi: 10.1093/jnci/djj155.
PMID:16622114
Abstract
摘要
相似文献
1
Assessing risk: does this patient have prostate cancer?
J Natl Cancer Inst. 2006 Apr 19;98(8):506-7. doi: 10.1093/jnci/djj155.
2
[Detection of prostate cancer: yes or no?].
Bull Mem Acad R Med Belg. 2006;161(3-4):159-69.
3
Screening for prostate cancer - will we ever know?
Acta Oncol. 2010 Apr;49(3):275-7. doi: 10.3109/02841861003696803.
4
Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10.
5
Prostate cancer: is the PSA test the answer?
N J Med. 1998 Mar;95(3):53-5.
6
Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
J Natl Cancer Inst. 2007 Sep 19;99(18):1395-400. doi: 10.1093/jnci/djm119. Epub 2007 Sep 11.
7
[Diagnosis of prostate cancer].
MMW Fortschr Med. 2010 May 13;152(19):40-2.
8
PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
Jpn J Clin Oncol. 2009 Nov;39(11):727-31. doi: 10.1093/jjco/hyp091. Epub 2009 Aug 12.
9
Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
Clin Prostate Cancer. 2002 Dec;1(3):142-4.
10
Efficacy vs effectiveness in prostate-specific antigen screening.
J Natl Cancer Inst. 2010 Mar 3;102(5):288-9. doi: 10.1093/jnci/djq002. Epub 2010 Feb 8.
引用本文的文献
1
The Risk Factors and Screening Uptake for Prostate Cancer: A Scoping Review.
Healthcare (Basel). 2023 Oct 20;11(20):2780. doi: 10.3390/healthcare11202780.
2
Prostate cancer regulatory networks.
J Cell Biochem. 2009 Aug 1;107(5):845-52. doi: 10.1002/jcb.22162.
3
The evolving biology and treatment of prostate cancer.
J Clin Invest. 2007 Sep;117(9):2351-61. doi: 10.1172/JCI31791.
Zotero 插件